Abstract 466P
Background
Extracellular matrix (ECM) plays a key role in tumorigenesis and progression. Collagen XII, expressed by the COL12A1 gene, is an important component of the ECM. COL12A1 is associated with tumorigenesis and poor prognosis in several cancers, but its role in breast cancer (BC) is unclear, especially the different expression between primary and metastasic foci of BC has not been reported.
Methods
We analyzed the expression of COL12A1 in tumor tissue and normal tissue, plotted a Kaplan-Meier curve by GEPIA, and analyzed mutation by COSMIC and cBioPortal in BC. PPI, GGI and pathway and process enrichment analysis were performed by STRING and Metascape. GeneMANIA was used to map gene interaction networks. BC cases with paired primary and metastatic foci were found out from TCGA database for analyzing different expression of COL12A1 in primary and metastatic foci. Immunohistochemical (IHC) staining was performed in paraffin tissue samples of paired primary lesion and lung metastases from triple-negative breast cancer (TNBC) patients.
Results
The results showed that COL12A1 in BC tissues was upregulated and was associated with poor prognosis of BC and the Luminal A+Luminal B subgroup. 3.04% of BC patients had COL12A1 gene alteration. Missense substitution (37.59%) was the most frequent mutation type. Among the 10 related genes, COL3A1, COL5A2, MMP12, P4HA1, P4HA2, P4HA3 and SERPINH1 were significantly upregulated in tumor tissue. The 20 most relevant genes in the GGI network are COL11A1, ID1, COL8A1, MMP9, COL5A1, MMP2, ISLR, LUM, COL7A1, COL3A1, COL1A2, MMP3, COL10A1, COL6A1, COL11A2, COL8A2, MMP8, MMP12. SERPINH1 and MMP13, which are enriched in several pathways including collagen degradation, collagen formation, collagen metabolic process, endodermal cell differentiation, collagen fibril organization and so on. Furthermore, analysis of paired cases from the TCGA-BRCA database revealed that COL12A1 was expressed with higher level in primary foci than metastatic foci. IHC staining revealed that the expression of COL12A1 was upregulated in primary foci of TNBC.
Conclusions
In conclusion, COL12A1 may be a poor prognostic predictor and a specific therapeutic target for primary foci in BC, especially in TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Suzhou Science and Technology Developing Projects (SKYD2022083, SYSD2020079 and SYSD2020075).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
478P - Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Presenter: Antonella Palazzo
Session: Poster session 04